Johnson & Johnson (JNJ)

111.34
2.60 2.30
NYSE : Health Care
Prev Close 113.91
Open 112.91
Day Low/High 111.15 / 113.30
52 Wk Low/High 96.04 / 126.07
Volume 6.81M
Avg Volume 7.07M
Exchange NYSE
Shares Outstanding 2.72B
Market Cap 310.55B
EPS 5.60
P/E Ratio 20.03
Div & Yield 3.20 (2.80%)

Latest News

Johnson & Johnson CEO Talks Trump, M&A After Mixed Earnings

Johnson & Johnson CEO Talks Trump, M&A After Mixed Earnings

CEO Alex Gorsky dishes a bit on Monday's meeting with President Trump during Johnson & Johnson's conference call.

Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now

Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now

Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.

3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter

3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter

Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may be worth buying.

Stocks Solidify Gains as DuPont, Alibaba Smash Earnings Estimates

Stocks Solidify Gains as DuPont, Alibaba Smash Earnings Estimates

Stocks move higher on Tuesday morning as earnings winners DuPont and Alibaba outpace weaker reports from the likes of Lockheed Martin.

Johnson & Johnson May Be Too Dependent on Pharma Revenue

Johnson & Johnson May Be Too Dependent on Pharma Revenue

There are many moving parts to J&J's latest earnings.

J&J Guides Lower for 2017 Despite Fourth-Quarter Beat

J&J Guides Lower for 2017 Despite Fourth-Quarter Beat

Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.

Stock Futures Little Changed Amid Flood of Earnings Reports

Stock Futures Little Changed Amid Flood of Earnings Reports

Stock futures are little changed on Tuesday morning as a rush of earnings reports leaves Wall Street torn on which direction to go.

Market Recon: Caught Between President Trump and the Fed

Market Recon: Caught Between President Trump and the Fed

The Fed's words can cause just as much volatility in the markets as the president's.

This Stock Got Creamed While You Slept

This Stock Got Creamed While You Slept

Oh, and the U.S. dollar continues to slide.

European Stocks Called Higher Amid Dollar Decline, Corporate Earnings Slate

European Stocks Called Higher Amid Dollar Decline, Corporate Earnings Slate

European stocks are expected to open firmer Tuesday as investors head into a busy corporate earnings season amid questions over the stability of economic policies from President Donald Trump.

The ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads

The ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads

Ethicon announces 510(k) clearance of the ECHELON FLEX™ GST SYSTEM (45mm)

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

What to Watch This Week: Trump's Presidency, Alphabet Earnings

What to Watch This Week: Trump's Presidency, Alphabet Earnings

For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

Ethicon Announces Acquisition Of Megadyne Medical Products, Inc.

Ethicon Announces Acquisition Of Megadyne Medical Products, Inc.

Complements and expands Ethicon's advanced energy portfolio with broad range of innovative electrosurgical tools

Intermediate Trade: Johnson & Johnson

Intermediate Trade: Johnson & Johnson

After an up-and-down year, this household name is as strong as ever.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.

Could Johnson & Johnson Rip Higher by 20%?

Could Johnson & Johnson Rip Higher by 20%?

It may just happen. Here is why.

JNJ, Actelion Reportedly Move Closer to a Deal

JNJ, Actelion Reportedly Move Closer to a Deal

A final deal could come as soon as this month, Bloomberg reported.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.